HIZPIRE Trademark

Trademark Overview

On Wednesday, January 17, 2024, a trademark application was filed for HIZPIRE with the United States Patent and Trademark Office. The USPTO has given the HIZPIRE trademark a serial number of 98978370. The federal status of this trademark filing is PUBLISHED FOR OPPOSITION as of Wednesday, June 17, 2026. This trademark is owned by CSL Behring L.L.C.. The HIZPIRE trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Providing medical and scientific research information in the field of pharmaceuticals and clinical trials
hizpire

General Information

Serial Number98978370
Word MarkHIZPIRE
Filing DateWednesday, January 17, 2024
Status686 - PUBLISHED FOR OPPOSITION
Status DateWednesday, June 17, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 29, 2025

Trademark Statements

Goods and ServicesProviding medical and scientific research information in the field of pharmaceuticals and clinical trials

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, February 6, 2024
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameCSL Behring L.L.C.
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressKing of Prussia, PA 19406
US
Party NameCSL Behring L.L.C.
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressKing of Prussia, PA 19406
US

Trademark Events

Event DateEvent Description
Saturday, January 20, 2024NEW APPLICATION ENTERED
Tuesday, February 6, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, February 20, 2024ASSIGNED TO EXAMINER
Tuesday, February 27, 2024NON-FINAL ACTION WRITTEN
Tuesday, February 27, 2024NON-FINAL ACTION E-MAILED
Tuesday, February 27, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, April 29, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, April 29, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, April 29, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, April 29, 2024SUSPENSION LETTER WRITTEN
Monday, April 29, 2024CORRESPONDENCE E-MAILED
Monday, January 27, 2025SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Wednesday, January 29, 2025SUSPENSION INQUIRY WRITTEN
Wednesday, January 29, 2025INQUIRY TO SUSPENSION E-MAILED
Wednesday, January 29, 2025NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Monday, March 3, 2025TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Monday, March 3, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, March 3, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, April 1, 2025APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, April 23, 2025NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 29, 2025PUBLISHED FOR OPPOSITION
Tuesday, April 29, 2025OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 24, 2025NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, July 9, 2025TEAS REQUEST TO DIVIDE RECEIVED
Monday, June 15, 2026CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, July 9, 2025DIVISIONAL REQUEST RECEIVED
Wednesday, June 17, 2026DIVISIONAL PROCESSING COMPLETE
Wednesday, July 9, 2025NOTICE OF ALLOWANCE CANCELLED
Wednesday, June 17, 20261(B) BASIS DELETED; PROCEED TO REGISTRATION

Related Keywords

hizpire pharmaceuticals clinical trials field information medical scientific research providing